Lung transplantation outcomes of patients with interstitial pneumonia with autoimmune features: a single-centre retrospective cohort study
Authors' conclusion
Post-transplant survival, lung function and complication rates were comparable between IPAF and IPF patients at one year and the last follow-up.
Study context
- Population
- Lung transplant recipients with interstitial lung disease (ILD) undergoing double lung transplantation, British Columbia, 1 January 2014 to 30 April 2024
- Participants
- 20 vs 64
- Exposure
- Interstitial pneumonia with autoimmune features (IPAF) vs IPF in double lung transplant recipients
- IPAFn = 20
- IPFn = 64reference
- Outcome
- Post-transplant outcomes:
- Survival
- Lung function
- Complications
- Follow-up
- 1 year and last
Methodological detailssingle-centre
- Single-centre
Main finding
As reported in the abstract
1-year and cumulative survival
- No difference in 1-year or cumulative survival, though survival curves diverged over time favouring IPAF
Observational data: associations, not effects.
Further findings
Female sex
P = 0.006
Pre-transplant immunosuppression
P < 0.001
Antifibrotic use
P < 0.001
| Outcome | IPAF | IPF | P value |
|---|---|---|---|
| Survival, non-UIP IPAF vs IPF (subgroup) | — not stated in the abstract | 66% | P = 0.044 |
— not stated in the abstract
- Survival, non-UIP IPAF vs IPF (subgroup): Non-UIP IPAF 100%
Post-transplant lung function, acute rejection, infection-related hospitalization, malignancy and chronic lung allograft dysfunction (CLAD)
- Similar between IPAF and IPF
Explant pathology
- More UIP patterns in IPF; IPAF showed more non-specific interstitial pneumonia (NSIP) or unclassifiable patterns
Original publication
Lung transplantation outcomes of patients with interstitial pneumonia with autoimmune features: a single-centre retrospective cohort study. Rheumatology (Oxford). Published 2 June 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →